How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

557 results for

Dermatitis Herpetiformis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Coeliac disease: recognition, assessment and management

, activate an abnormal mucosal immune response. Clinical and histological improvements usually follow when gluten is excluded from the diet. Coeliac disease can present with a wide range of clinical features, both gastrointestinal (such as indigestion, diarrhoea, abdominal pain, bloating, distension or constipation) and non-gastrointestinal (such as fatigue, dermatitis herpetiformis, anaemia, osteoporosis, reproductive problems, neuropathy, ataxia or delayed puberty). Children may also present

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

182. Celiac Disease

from normal mucosa to subtotal/total villous atrophy in patients with celiac disease. The modified Marsh classification is widely used in clinical practice [73,76]. Another simpler classification has been proposed in order to minimize intraobserver variability [77]. Table 5 Modified Marsh classification of gluten-induced small-intestinal damage [73,76] Stage 0 Pre-infiltrative mucosa; up to 30% of patients with dermatitis herpetiformis (DH) or gluten ataxia have small-intestinal biopsy specimens (...) and they should be followed up and the original biopsy reviewed. The majority of potential celiac disease patients later develop celiac disease. ? In addition, 30% of patients with dermatitis herpetiformis who have positive serology findings have normal histology. However, a GFD is recommended even with negative histology, as it restores positive serology and skin lesions. ? Asymptomatic individuals with titers just at the cut-off level (borderline) should be retested after 3–6 months on a normal diet

2016 World Gastroenterology Organisation

183. NASPGHAN Clinical Report on the Diagnosis and Treatment of Gluten-related Disorders

be associated with CD. Anemia, most commonly as a result of iron deficiency, has been reported in 12% to 69% of newly diagnosed patients (15–18) and appears more prevalent in celiac patients with an atrophic mucosa compared with those with mild enteropathy (19). Linear growth failure as an isolated initial presentation of CD is well described and can be found in up to 10% of children undergoing investigation for short stature (20,21). Dermatitis herpetiformis (DH) is considered a skin presen- tation of CD (...) dermatitis X Fatigue X X X Headache/migraine X X X Foggy mind X X Angioedema X Anaphylaxis X Respiratory Asthma X Cough X Postnasal drip, throat clearing, rhinitis X DH¼ dermatitis herpetiformis; NCGS¼ nonceliac gluten sensitivity; WA¼ wheat allergy. JPGN Volume 63, Number 1, July 2016 NASPGHAN Clinical Report on Gluten-related Disorders www.jpgn.org 157 Copyright © ESPGHAL and NASPGHAN. All rights reserved. mineral density appear better able to correct this deficiency after starting the GFD, recovery

2016 North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

184. Diagnosis of Celiac Disease

transglutaminase (tTG) is an enzyme involved in the cross-linking of certain proteins. This test is included in the algorithms of all recent guidelines. Other tests may be ordered for individuals who are IgA deficient. Endomysial antibodies, IgA The endomysium is the thin connective-tissue layer covering individual muscle fibers. Endomysial antibodies (EmA) develop when the intestinal lining is damaged. Most patients with active celiac disease and many others with dermatitis herpetiformis have anti-EmA IgA

2016 Effective Health Care Program (AHRQ)

185. Management of scabies

Differential diagnosis Scabies frequently imitates other skin diseases. It is important to have a high degree of suspicion to recognise symptoms and signs of scabies. Differential diagnosis for scabies include: Impetigo, folliculitis, papular urticarial, atopic dermatitis, contact dermatitis, dermatitis herpetiformis, psoriasis, seborrhoeic dermatitis, pytiriasis rosea, secondary syphilis and lymphoma and pseudolymphoma (if scabies presents with nodules). Complications Secondary bacterial infection due

2016 British Association for Sexual Health and HIV

186. Review of Autoimmune Blistering Diseases: the Pemphigoid diseases. (PubMed)

Review of Autoimmune Blistering Diseases: the Pemphigoid diseases. Autoimmune Blistering Diseases of the Pemphigoid type is characterised by sub-epidermal blisters (SEB) with circulating autoantibodies against components of the basement membrane zone (BMZ). The main disorders to date include bullous pemphigoid (BP), pemphigoid gestationis, mucous membrane pemphigoid (MMP), epidermolysis bullosa acquisita (EBA), linear IgA disease (LABD), dermatitis herpetiformis (DH), lichen planus pemphigoides

2019 Journal of the European Academy of Dermatology and Venereology

187. [Is gluten the great etiopathogenic agent of disease in the XXI century?].

, autism spectrum disorder, schizophrenia, attention deficit hyperactivity disorder, depressive disorders, headaches, irritable bowel syndrome, fibromyalgia, dermatitis herpetiformis and epilepsy, studies in which either a determination of gliadin was refered or a treatment, with/without gluten, was applied and evaluated.The ingestion of gluten seems to be related to disease, when there is no EC, SGNC or wheat allergy. Suspicions about the benefit of GF D as a complementary treatment is borne in semi

2016 Nutricion hospitalaria

188. Cholinergic Urticaria

-, delayed pressure-, aquagenic-, or contact-urticaria These diseases are allowed a comorbidities, if cholinergic urticaria is the dominating form of chronic urticaria Any other severe skin disease associated with chronic itching that might confound the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus etc.) Previous treatment with omalizumab within 3 months prior to screening. History of anaphylactic shock. Contacts and Locations Go (...) with Dupilumab has been shown to reduce clinically significant exacerbations and to improve skin symptom control as well as quality of life in moderate to severe atopic dermatitis patients and in moderate to severe asthma patients. It has been approval by EMA for the treatment of atopic dermatitis patients in September 2017. Dupilumab is a novel monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in atopic dermatitis and asthma

2018 Clinical Trials

189. Dupilumab in Chronic Spontaneous Urticaria

urticaria. Other diseases with symptoms of urticaria or angioedema, including urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency) Any other skin disease associated with chronic itching that might confound the study evaluations and results (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, etc.) Previous exposure to omalizumab in last 3 months History of anaphylactic (...) : Placebo Phase 2 Detailed Description: Treatment with Dupilumab has been shown to reduce clinically significant exacerbations and to improve skin symptom control as well as quality of life in moderate to severe atopic dermatitis patients and in moderate to severe asthma patients. It has been approval by European Medicines Agency (EMA) for the treatment of atopic dermatitis patients in September 2017. Dupilumab is a novel monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13

2018 Clinical Trials

191. Extra-intestinal manifestations of non-celiac gluten sensitivity: An expanding paradigm (PubMed)

, joint and muscle pain, leg or arm numbness even if more specific complaints have been described. NCGS has an immune-related background. Indeed there is a strong evidence that a selective activation of innate immunity may be the trigger for NCGS inflammatory response. The most commonly autoimmune disorders associated to NCGS are Hashimoto thyroiditis, dermatitis herpetiformis, psoriasis and rheumatologic diseases. The predominance of Hashimoto thyroiditis represents an interesting finding, since

Full Text available with Trip Pro

2018 World Journal of Gastroenterology

192. Cutaneous and Mucosal Manifestations Associated with Celiac Disease (PubMed)

Cutaneous and Mucosal Manifestations Associated with Celiac Disease Celiac disease (CD) is an immune-mediated, gluten-induced enteropathy that affects predisposed individuals of all ages. Many patients with CD do not report gastrointestinal symptoms making it difficult to reach an early diagnosis. On the other hand, CD is related to a wide spectrum of extra-intestinal manifestations, with dermatitis herpetiformis (DH) being the best characterized. These associated conditions may be the clue

Full Text available with Trip Pro

2018 Nutrients

193. Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction (PubMed)

as extracellular substrates for GzmB through western blot, and specific cleavage sites were identified by mass spectrometry. In human bullous pemphigoid, dermatitis herpetiformis, and epidermolysis bullosa acquisita, GzmB was elevated at the DEJ when compared to healthy samples, while α6/β4 integrin, collagen VII, and collagen XVII were reduced or absent in the area of blistering. In summary, our results suggest that regardless of the initial causation of sub-epidermal blistering, GzmB activity is a common

Full Text available with Trip Pro

2018 Scientific reports

194. Freestyle Libre Flash Glucose Monitoring System

include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema. Subject has had an episode of severe hypoglycemia requiring intervention from a health care professional (i.e. EMT assistance, emergency room visit, or hospital admission) within the last three (3) months. Subject is currently participating in another clinical trial. Subject has donated blood within 112 days (3.7

2018 Clinical Trials

195. FreeStyle Libre Glucose Monitoring System in Pediatric Populations

application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema. Subject is currently participating in another clinical trial. Subject has had significant blood loss within 112 days (3.7 months) prior to the beginning of the study activities subjects

2018 Clinical Trials

196. Trichoscopy in Diagnosis of Immunobollous Diseases

Party): tasbeeh salah, Assiut University Study Details Study Description Go to Brief Summary: Autoimmune bullous diseases are a variety of skin diseases that are characterized by the presence of bullae or blisters. Most of these diseases are associated with substantial morbidity and mortality. They are classified according to the site of blister formation into intraepidermal as pemphigus valgaris and foliaceus, and subepidermal as bullous pemphigoid and dermatitis herpetiformis. These lesions (...) of these diseases are associated with substantial morbidity and mortality. They are classified according to the site of blister formation into intraepidermal as pemphigus valgaris and foliaceus, and subepidermal as bullous pemphigoid and dermatitis herpetiformis. These lesions commonly affect the scalp and manifest as blisters, erosions and crustations. Pemphigus is a group of potentially life-threatening intraepidermal vesiculobullous autoimmune diseases that affect the skin and mucous membranes

2018 Clinical Trials

197. Latiglutenase as a Treatment for Celiac Disease

Criteria: Active dermatitis herpetiformis at the time of screening IBS (Irritable Bowel Syndrome) History of any form of colitis Received any systemic biologics (such as monoclonal antibodies or other protein therapeutics where the half-life overlaps with the study start) within 6 months prior to study start Taking any oral probiotic supplements (not including probiotics contained in commercially available food preparations) 6 months prior to entry Use of any immunosuppressive medications (i.e

2018 Clinical Trials

198. Does the Disinfection of the Subcutaneous Tissue Reduce the Contamination of the Operative Field by P. Acnes During Primary Shoulder Surgery?

of the shoulder Antibiotherapy in the 2 weeks preceding the intervention Infiltration of cortisone in the 6 months preceding the intervention Iodinated contrast medium allergy or cefuroxime Allergy to the povidone iodine complex or other contraindication to Betadine namely: Hypersensitivity to the active ingredient, iodine or povidone iodine complex, or to any of the excipients according to the composition. Hyperthyroidism and other overt thyroid diseases. Dermatitis herpetiformis of Duhring. Before and after

2018 Clinical Trials

199. A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines

opinion the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.). Prior exposure to ligelizumab or omalizumab. Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at greater than approved doses after Visit 1. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

200. A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

opinion the study evaluations and results (e.g. atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.). Prior exposure to ligelizumab or omalizumab. Any H2 antihistamine, LTRA (montelukast or zafirlukast) or H1 antihistamines use at greater than approved doses after Visit 1. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>